CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy

OBJECTIVE: Third-generation aromatase inhibitors (AI) are potent suppressors of aromatase activity. The aim of this study was to measure the incidence of adverse effects in breast cancer patients treated with AI-based adjuvant therapy and the relationship with the CYP19A1 genotypes. MATERIALS AND ME...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eurasian J Med
Autors principals: Mazzuca, Federica, Botticelli, Andrea, Mazzotti, Eva, La Torre, Marco, Borro, Marina, Marchetti, Luca, Maddalena, Chiara, Gentile, Giovanna, Simmaco, Maurizio, Marchetti, Paolo
Format: Artigo
Idioma:Inglês
Publicat: The Eurasian Journal of Medicine 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4792488/
https://ncbi.nlm.nih.gov/pubmed/27026757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/eurasianjmed.2015.008
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars